Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics

Cancer Treatment Reviews

Volumn 39, Issue 7, 2013, Pages 691-700

  Onstenk, W ^a   Gratama, J W ^a   Foekens, J A ^a   Sleijfer, S ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Breast cancer; Characterization; Circulating tumor cells; CTC; ER; HER2; Predictive

Indexed keywords

CYTOKERATIN; DOUBLE STRANDED DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GAMMA UROGASTRONE; LAPATINIB; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; APOPTOSIS; BREAST CANCER; CANCER CELL; CHROMOSOME ABERRATION; CIRCULATING TUMOR CELL; CLINICAL STUDY; DENSITY GRADIENT CENTRIFUGATION; DISEASE FREE SURVIVAL; DNA DAMAGE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; IMAGE CYTOMETRY; IMMUNOASSAY; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; LEUKOCYTE; PERSONALIZED MEDICINE; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; VEIN PUNCTURE;

BREAST CANCER; CHARACTERIZATION; CIRCULATING TUMOR CELLS; CTC; ER; HER2; PREDICTIVE;

BREAST NEOPLASMS; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84881555649     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.04.001     Document Type: Review

References (63)

1. Navin N., Kendall J., Troge J., et al. Tumour evolution inferred by single-cell sequencing. Nature 2011, 472(7341):90-94.
2. Turner N.C., Reis-Filho J.S. Genetic heterogeneity and cancer drug resistance. Lancet Oncol 2012, 13(4):178-185.
3. Lindstrom L.S., Karlsson E., Wilking U.M., et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012, 30(21):2601-2608.
4. Zhang L., Riethdorf S., Wu G., et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 2012, 18(20):5701-5710.
5. Mostert B., Sleijfer S., Foekens J.A., Gratama J.W. Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev 2009 Aug, 35(5):463-474.
6. Cristofanilli M., Budd G.T., Ellis M.J., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004 Aug 19, 351(8):781-791.
7. Lucci A., Hall C.S., Lodhi A.K., et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 2012, 13(7):688-695.
8. Iwatsuki M., Mimori K., Yokobori T., et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 2010 Feb, 101(2):293-299.
9. Sieuwerts A.M., Kraan J., Bolt J., et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Instrum 2009, 101(1):61-66.
10. Punnoose E.A., Atwal S.K., Spoerke J.M., et al. Molecular biomarker analyses using circulating tumor cells. PLoS One 2010, 5(9):e12517.
11. Pestrin M., Bessi S., Galardi F., et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 2009 Dec, 118(3):523-530.
12. Meng S., Tripathy D., Shete S., et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004, 101(25):9393-9398.
13. Ignatiadis M., Rothe F., Chaboteaux C., et al. HER2-positive circulating tumor cells in breast cancer. PLoS One 2011, 6(1):e15624.
14. Riethdorf S., Muller V., Zhang L., et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010 May 1, 16(9):2634-2645.
15. Ligthart S.T., Bidard F.C., Decraene C., et al. Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer. Ann Oncol 2012.
16. Fehm T., Muller V., Aktas B., et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat 2010 Nov, 124(2):403-412.
17. Apostolaki S., Perraki M., Kallergi G., et al. Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. Breast Cancer Res Treat 2009, 117(3):525-534.
18. Georgoulias V., Bozionelou V., Agelaki S., et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. Ann Oncol 2012, 23(7):1744-1750.
19. Payne R.E., Yague E., Slade M.J., et al. Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics 2009, 10(1):51-57.
20. Lowes L.E., Hedley B.D., Keeney M., Allan A.L. User-defined protein marker assay development for characterization of circulating tumor cells using the Cell Search(R) system. Cytometry A 2012, 81(11):983-995.
21. Ignatiadis M., Kallergi G., Ntoulia M., et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res 2008, 14(9):2593-2600.
22. Kallergi G., Agelaki S., Kalykaki A., et al. Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Res 2008, 10(5):R80.
23. Nadal R., Fernandez A., Sanchez-Rovira P., et al. Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res 2012, 14(3):R71.
24. Fehm T., Becker S., Duerr-Stoerzer S., et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res 2007, 9(5):R74.
25. Blokzijl A., Friedman M., Ponten F., Landegren U. Profiling protein expression and interactions: proximity ligation as a tool for personalized medicine. J Intern Med 2010, 268(3):232-245.
26. Kim P., Liu X., Lee T., et al. Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients. Proteome Sci 2011, 9(1):75.
27. Gradilone A., Naso G., Raimondi C., et al. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Ann Oncol 2011, 22(1):86-92.
28. Markou A., Strati A., Malamos N., Georgoulias V., Lianidou E.S. Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. Clin Chem 2011, 57(3):421-430.
29. Raimondi C., Gradilone A., Naso G., et al. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat 2011, 130(2):449-455.
30. Strati A., Markou A., Parisi C., et al. Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. BMC Cancer 2011, 11:422.
31. Tewes M., Aktas B., Welt A., et al. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 2009, 115(3):581-590.
32. Sieuwerts A.M., Kraan J. Bolt-de Vries J, et al. Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res Treat 2009, 118(3):455-468.
33. Sieuwerts A.M., Mostert B., Bolt-de Vries J., et al. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res 2011, 17(11):3600-3618.
34. Smirnov D.A., Zweitzig D.R., Foulk B.W., et al. Global gene expression profiling of circulating tumor cells. Cancer Res 2005, 65(12):4993-4997.
35. Fehm T., Hoffmann O., Aktas B., et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 2009, 11(4):R59.
36. Aktas B., Tewes M., Fehm T., et al. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009, 11(4):R46.
37. Andreopoulou E., Yang L.Y., Rangel K.M., et al. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect versus Veridex Cell Search system. Int J Cancer [Clinical Trial Research Support, Non-U.S. Gov't] 2012, 130(7):1590-1597.
38. Aktas B., Muller V., Tewes M., et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol 2011, 122(2):356-360.
39. Banys M., Krawczyk N., Becker S., et al. The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer. Breast Cancer Res Treat 2012, 132(1):121-129.
40. Bozionellou V., Mavroudis D., Perraki M., et al. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res 2004, 10(24):8185-8194.
41. Apostolaki S., Perraki M., Pallis A., et al. Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. Ann Oncol 2007, 18(5):851-858.
42. Ignatiadis M., Xenidis N., Perraki M., et al. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 2007, 25(33):5194-5202.
43. Fehm T., Sagalowsky A., Clifford E., et al. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 2002, 8(7):2073-2084.
44. Flores L.M., Kindelberger D.W., Ligon A.H., et al. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br J Cancer 2010, 102(10):1495-1502.
45. Mayer J.A., Pham T., Wong K.L., et al. FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE platform. Cancer Genet 2011, 204(11):589-595.
46. Pestrin M., Bessi S., Puglisi F., et al. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells A proof-of-concept study. Breast Cancer Res Treat 2012.
47. Hayashi N., Nakamura S., Tokuda Y., et al. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int J Clin Oncol 2012, 17(2):96-104.
48. Swennenhuis J.F., Tibbe A.G., Levink R., Sipkema R.C., Terstappen L.W. Characterization of circulating tumor cells by fluorescence in situ hybridization. Cytometry A 2009, 75(6):520-527.
49. Navin N., Hicks J. Future medical applications of single-cell sequencing in cancer. Genome Med 2011, 3(5):31.
50. Bednarz-Knoll N., Alix-Panabieres C., Pantel K. Clinical relevance and biology of circulating tumor cells. Breast Cancer Res 2011, 13(6):228.
51. Magbanua M.J., Sosa E.V., Roy R., et al. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res 2013, 73(1):30-40.
52. Meng S., Tripathy D., Shete S., et al. UPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA 2006, 103(46):17361-17365.
53. Munzone E., Nole F., Goldhirsch A., et al. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin Breast Cancer 2010, 10(5):392-397.
54. Resel Folkersma L., San Jose Manso L., Galante Romo I., Moreno Sierra J., Olivier Gomez C. Prognostic Significance of Circulating Tumor Cell Count in Patients With Metastatic Hormone-sensitive Prostate Cancer. Urology 2012, 80(6):1328-1332.
55. Andreopoulou E., Cristofanilli M. Circulating tumor cells as prognostic marker in metastatic breast cancer. Expert Rev Anticancer Ther 2010, 10(2):171-177.
56. Wulfing P., Borchard J., Buerger H., et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 2006, 12(6):1715-1720.
57. Somlo G., Lau S.K., Frankel P., et al. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat 2011, 128(1):155-163.
58. Wulfkuhle J.D., Berg D., Wolff C., et al. Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping. Clin Cancer Res 2012, 18(23):6426-6435.
59. Martin L.P., Hamilton T.C., Schilder R.J. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008, 14(5):1291-1295.
60. Garcia-Villa A., Balasubramanian P., Miller B.L., et al. Assessment of gamma-H2AX levels in circulating tumor cells from patients receiving chemotherapy. Front Oncol 2012, 2:128.
61. Rossi E., Basso U., Celadin R., et al. M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by Cell Search analysis. Clin Cancer Res 2010, 16(21):5233-5243.
62. Diaz L.A., Williams R.T., Wu J., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012, 486(7404):537-540.
63. Misale S., Yaeger R., Hobor S., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486(7404):532-536.